Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1

Interventions

venetoclax 152Cytarabine 114Cyclophosphamide 110Specimen Handling 101Azacitidine 99fludarabine 89Biopsy 76Rituximab 48Methotrexate 45Daunorubicin 44fludarabine phosphate 42Vincristine 38Dexamethasone 37Magnetic Resonance Spectroscopy 36Injections 34Decitabine 34blinatumomab 31Granulocyte Colony-Stimulating Factor 30Mycophenolic Acid 29Whole-Body Irradiation 28Prednisone 28Idarubicin 28ibrutinib 27Tacrolimus 27Etoposide 27Doxorubicin 27Busulfan 27Melphalan 24acalabrutinib 23Mercaptopurine 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
EPOCH protocol × Other hematologic neoplasm × 90 days × Clear all
NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡